Mental Health and Cognitive Function Statistics (2026)

Last Updated: June 2026

Mental health and cognitive function are not parallel tracks that occasionally intersect. They are deeply intertwined systems, each shaping the other through shared neurological mechanisms. Depression reduces hippocampal volume and impairs memory consolidation. Chronic anxiety floods the brain with cortisol and narrows attentional focus. Schizophrenia disrupts the prefrontal circuits that govern working memory and executive function. The relationship is not metaphorical — it is structural, measurable, and in many cases reversible with appropriate intervention.

Understanding the scale of mental illness globally, the cognitive consequences of specific conditions, and the state of treatment access is essential for anyone seeking to understand brain health comprehensively. The statistics in this article are drawn from the National Institute of Mental Health (NIMH), the World Health Organization (WHO), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Institute for Health Metrics and Evaluation (IHME), and peer-reviewed journals including JAMA Psychiatry, The Lancet Psychiatry, and Nature Neuroscience.

For a broader overview of how mental health data fits within the full landscape of brain health research, see our flagship article Brain Health Statistics: 50+ Key Facts (2026).

Key Mental Health and Cognitive Function Statistics at a Glance

• An estimated 970 million people worldwide — roughly one in eight — live with a mental health or substance use disorder. (WHO, 2022)
• Nearly 1 in 5 U.S. adults experiences a mental illness in any given year, totaling approximately 57.8 million people. (NIMH)
• Depression is associated with up to 20% reduction in hippocampal volume in individuals with recurrent major depressive episodes. (British Journal of Psychiatry)
• People with untreated depression are 2.5 times more likely to develop dementia later in life. (JAMA Psychiatry)
• Anxiety disorders affect an estimated 284 million people globally, making them the most prevalent category of mental health conditions. (IHME)
• Only about 50% of people with a mental illness in high-income countries receive any form of treatment. (WHO)
• Mental health conditions account for one in six years lived with disability worldwide. (WHO)

Global Prevalence of Mental Health Conditions

Mental illness is among the most prevalent categories of disease burden globally, affecting populations across every income level, region, and demographic. Its scale is rarely reflected in the funding and infrastructure dedicated to addressing it.

Overall Global Numbers

The most recent global estimates paint a picture of a condition category that dwarfs many better-funded diseases in both prevalence and disability burden.

• An estimated 970 million people worldwide live with a mental health or substance use disorder — roughly one in eight people on earth. (WHO, 2022)
  This figure includes anxiety disorders, depressive disorders, bipolar disorder, schizophrenia, eating disorders, and substance use disorders, but does not capture the full scope of mental health conditions globally.
• Mental health conditions account for one in six years lived with disability worldwide, placing them among the leading contributors to the global burden of disease. (WHO)
  Despite this burden, mental health historically receives a disproportionately small share of national health budgets — averaging less than 2% of government health spending globally.
• The COVID-19 pandemic triggered a 25% increase in the prevalence of anxiety and depression globally in its first year alone. (WHO, 2022)
  Much of this increase has persisted, with mental health systems in many countries still managing elevated post-pandemic demand without commensurate increases in capacity.
• Globally, mental and substance use disorders are the leading cause of disability among people aged 10 to 29, a demographic in the critical window of brain development. (The Lancet)
  The onset of most major psychiatric conditions occurs before age 25, making adolescent and young adult mental health one of the highest-leverage areas for long-term brain health investment.

Mental Health in the United States

U.S.-specific data from NIMH and SAMHSA provides some of the most detailed national mental health statistics available, including breakdowns by condition, age, sex, and race.

• Nearly 1 in 5 U.S. adults — approximately 57.8 million people — experiences a mental illness in any given year. (NIMH)
  Serious mental illness, defined as conditions substantially limiting major life activities, affects approximately 14.1 million U.S. adults annually.
• Approximately 1 in 6 U.S. youth aged 6 to 17 experiences a mental health disorder each year. (NIMH)
  The rate of diagnosed mental health conditions in children and adolescents has risen substantially over the past two decades, with debate continuing over whether this reflects true incidence increases, improved detection, or both.
• Suicide is the second leading cause of death among Americans aged 10 to 34 and the twelfth leading cause of death overall. (CDC)
  More than 90% of people who die by suicide had a diagnosable mental health condition at the time of death, underscoring the life-or-death stakes of treatment access and quality.
• The economic cost of mental illness in the United States exceeds $280 billion annually, including healthcare costs, lost productivity, and disability payments. (NIMH)
  This figure underestimates the true societal cost by excluding informal caregiving, reduced educational attainment, and the downstream effects on families and communities.

Depression: Cognitive Consequences and Brain Impact

Major depressive disorder is the most common psychiatric condition globally and one of the most significant contributors to cognitive impairment across the lifespan. Its effects on brain structure and function are well-documented, measurable, and in many cases partially reversible with treatment.

Prevalence and Scale

Depression is both widespread and frequently undertreated, creating a large population living with its cognitive consequences without adequate support.

• Major depressive disorder affects approximately 280 million people worldwide, making it one of the leading causes of disability globally. (WHO)
  The condition is characterized by persistent low mood, loss of interest, disrupted sleep and appetite, fatigue, and — critically for brain health — impaired memory, concentration, and decision-making.
• In the United States, approximately 21 million adults experienced at least one major depressive episode in 2022, representing 8.3% of all U.S. adults. (NIMH)
  Rates are highest among adults aged 18 to 25, with young women showing the highest prevalence of any demographic group.
• Postpartum depression affects approximately 1 in 8 women in the United States following childbirth. (CDC)
  Untreated postpartum depression is associated with impaired cognitive function in both the mother and, through disrupted early caregiving, in the developing child.

Depression and Brain Structure

The structural brain changes associated with depression are among the most extensively studied in all of psychiatry. They help explain why depression is not simply a matter of mood — it is a condition with measurable neurological consequences.

• Depression is associated with measurable reductions in hippocampal volume, with studies showing up to 20% shrinkage in individuals with recurrent major depressive episodes. (British Journal of Psychiatry)
  The hippocampus is central to memory formation and spatial navigation — which explains why impaired memory and disorientation are common features of clinical depression rather than mere side effects of low mood.
• Each additional depressive episode is associated with further hippocampal volume loss, suggesting that untreated recurrent depression has a compounding neurological cost over time. (Molecular Psychiatry)
  This finding makes early and effective treatment not only a quality-of-life matter but a neurological preservation one.
• Antidepressant treatment, particularly with SSRIs, is associated with partial hippocampal volume recovery in individuals who respond to medication. (Neuropsychopharmacology)
  Neurogenesis — the growth of new neurons — in the hippocampus is promoted by SSRI treatment and may be part of the mechanism through which these medications exert their antidepressant effect.
• Depression is associated with reduced activity in the prefrontal cortex — the region governing executive function, planning, and cognitive control — and hyperactivity in the amygdala. (Nature Neuroscience)
  This imbalance produces the characteristic combination of emotional flooding and impaired rational control that characterizes severe depressive episodes.
• People with untreated depression are 2.5 times more likely to develop dementia later in life. (JAMA Psychiatry)
  Whether depression is a causal risk factor, an early prodrome of neurodegeneration, or both remains under active investigation — but the statistical association is consistent across multiple large longitudinal studies.

Anxiety Disorders: Cognitive Impact and Brain Effects

Anxiety disorders are the most prevalent category of mental health conditions globally, and their cognitive consequences are substantial and frequently underappreciated. Chronic anxiety is not simply a state of worry — it is a condition that alters brain architecture, impairs attentional control, and degrades performance across multiple cognitive domains.

Prevalence of Anxiety Disorders

The scale of anxiety disorders globally exceeds that of depression, yet they are often treated as less serious — a perception the data does not support.

• Anxiety disorders affect an estimated 284 million people globally, making them the most common category of mental health conditions worldwide. (IHME)
  The category includes generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobias, and separation anxiety disorder — conditions that vary in presentation but share common neurological underpinnings.
• In the United States, anxiety disorders affect approximately 40 million adults annually — about 18% of the population — making them the most common mental illness in the country. (Anxiety and Depression Association of America)
  Despite their prevalence, only about 37% of those affected receive treatment, reflecting a combination of stigma, access barriers, and symptom normalization.
• Generalized anxiety disorder (GAD) is associated with a 10-year reduction in quality-adjusted life years in untreated individuals, comparable in impact to chronic physical conditions such as diabetes. (The Lancet Psychiatry)
  The functional impairment associated with GAD — in work performance, relationships, and cognitive function — extends well beyond subjective distress.

Anxiety and Brain Function

The neurological effects of chronic anxiety are distinct from those of acute stress, though they share some common mechanisms. The cumulative impact of sustained anxiety on brain structure and cognitive performance is increasingly well-documented.

• Chronic anxiety is associated with hyperactivation of the amygdala and reduced prefrontal cortex control over emotional responses. (Nature Neuroscience)
  Over time, this pattern — which mirrors the structural effects of chronic stress — weakens the brain’s capacity for top-down regulation of fear and threat responses.
• Anxiety impairs working memory by consuming attentional resources with threat-monitoring processes that compete with task-relevant cognitive demands. (Psychological Science)
  This attentional competition explains why anxious individuals often perform worse on cognitively demanding tasks even when they are highly motivated and technically capable.
• Individuals with high trait anxiety show measurable differences in white matter connectivity in regions linking the prefrontal cortex and amygdala, compared to low-anxiety individuals. (NeuroImage)
  White matter integrity in these pathways is associated with emotional regulation capacity — its disruption contributes to the difficulty anxious individuals have in “talking themselves down” from anxious states.
• Anxiety disorders double the risk of developing depression, creating a compounding neurological burden when both conditions are present simultaneously. (JAMA Psychiatry)
  Comorbid anxiety and depression — which occur together in approximately 50% of cases — are associated with more severe cognitive impairment than either condition alone.

PTSD and Trauma: Effects on the Brain

Post-traumatic stress disorder (PTSD) is among the conditions with the most extensively documented neurological signatures. Its effects on brain structure, function, and cognitive performance are measurable, distinctive, and increasingly understood at the level of specific neural circuits.

• Approximately 3.6% of U.S. adults — about 9 million people — have PTSD in any given year. (NIMH)
  Lifetime prevalence is approximately 6.8%, with women roughly twice as likely as men to develop PTSD following trauma exposure.
• Veterans have a PTSD prevalence rate of 11 to 20% in any given year, depending on era of service and deployment history. (U.S. Department of Veterans Affairs)
  Combat-related PTSD is often complicated by comorbid traumatic brain injury, creating overlapping cognitive impairments that complicate both diagnosis and treatment.
• PTSD is associated with reduced hippocampal volume comparable to that seen in major depression, along with hyperactivation of the amygdala and reduced prefrontal cortex regulation. (Biological Psychiatry)
  Whether hippocampal reduction precedes trauma and confers vulnerability, or results from the trauma itself, has been a central question in PTSD neuroscience — evidence now supports both pathways.
• People with PTSD show impaired performance on tasks requiring verbal memory, attention, and executive function, with deficits that are measurable even during periods of symptom remission. (Neuropsychology Review)
  These persistent cognitive impairments are not simply consequences of sleep disruption or hypervigilance — they reflect underlying changes in the neural circuitry supporting cognition.
• Trauma-focused cognitive behavioral therapy (TF-CBT) and EMDR have demonstrated efficacy rates of 60 to 80% in reducing PTSD symptoms in clinical trials. (APA Clinical Practice Guideline)
  Neuroimaging studies show that successful PTSD treatment is associated with measurable changes in amygdala reactivity and prefrontal activation — confirming that effective therapy produces real neurological change, not just symptom suppression.
• Childhood trauma is associated with a 40 to 60% increased risk of developing a psychiatric disorder in adulthood, as well as structural changes in the developing brain that can persist for decades. (JAMA Pediatrics)
  Adverse childhood experiences (ACEs) alter the stress response system during critical developmental windows, with consequences for cognitive development, emotional regulation, and long-term mental health.

The relationship between stress hormones and brain structure is explored further in our article on Stress and the Brain: Key Statistics.

Bipolar Disorder and Cognitive Function

Bipolar disorder is a condition characterized by episodes of mania or hypomania alternating with depression. Beyond its mood features, it produces distinct and persistent cognitive impairments that affect functioning even during periods of mood stability.

• Bipolar disorder affects approximately 40 million people worldwide and about 2.8% of U.S. adults in any given year. (WHO, NIMH)
  It is among the most disabling of psychiatric conditions, with a significant proportion of affected individuals unable to maintain full employment due to cognitive and functional impairment.
• Cognitive impairments in bipolar disorder — including deficits in attention, verbal memory, and processing speed — persist during euthymic (mood-stable) periods, not only during episodes. (Psychological Medicine)
  This persistence suggests that cognitive impairment is a core feature of the disorder rather than a consequence of acute mood states.
• People with bipolar disorder show reduced gray matter volume in the prefrontal cortex and hippocampus compared to healthy controls, with greater reductions in individuals with more illness episodes. (Neuropsychopharmacology)
  The episode-related progression of structural changes reinforces the neurological case for mood stability as a treatment goal, not merely a quality-of-life one.
• Lithium — the most established mood stabilizer for bipolar disorder — is associated with increased gray matter volume in the prefrontal cortex and hippocampus, and with reduced dementia risk in long-term users. (The Lancet)
  Lithium’s neuroprotective properties have generated significant interest in its potential role in Alzheimer’s prevention, with clinical trials ongoing.

Schizophrenia and Cognitive Impairment

Schizophrenia is among the most cognitively disabling of psychiatric conditions. While its psychotic symptoms — hallucinations and delusions — are most visible, the cognitive deficits that accompany the condition are often its most functionally limiting feature.

• Schizophrenia affects approximately 24 million people worldwide — about 1 in 300 of the global population. (WHO)
  It is one of the leading causes of disability among young adults globally, with onset typically occurring in late adolescence or early adulthood.
• Cognitive impairment is present in approximately 80% of people with schizophrenia, affecting working memory, attention, processing speed, and executive function. (Schizophrenia Research)
  These cognitive deficits are often more functionally disabling than the positive psychotic symptoms and are less responsive to currently available antipsychotic medications.
• People with schizophrenia score an average of 1.5 standard deviations below healthy controls on cognitive testing, a deficit that is present from the earliest stages of the illness and that precedes the onset of psychosis. (Archives of General Psychiatry)
  The pre-morbid cognitive deficit suggests that schizophrenia involves a disruption of normal neurodevelopmental processes rather than a deterioration that begins at symptom onset.
• Schizophrenia is associated with accelerated brain aging, with affected individuals showing brain structure patterns typically associated with individuals 10 to 15 years older. (Nature Neuroscience)
  This accelerated aging is driven by a combination of the disease process itself, the effects of antipsychotic medications on brain structure, and lifestyle factors common in this population.

ADHD and Cognitive Function

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning. It is among the most diagnosed psychiatric conditions in children and is increasingly recognized as a lifelong condition extending into adulthood.

• ADHD affects approximately 5.9% of children and 2.5% of adults worldwide. (JAMA Psychiatry)
  In the United States, ADHD diagnosis rates are higher, with approximately 9.4% of children aged 2 to 17 having received a diagnosis at some point. (CDC)
• ADHD is associated with delayed cortical maturation — the brain’s prefrontal cortex matures three to five years later in children with ADHD compared to neurotypical peers. (PNAS)
  This developmental delay explains why behaviors that appear abnormal in a child with ADHD may represent a lag in executive function development rather than a fixed deficit.
• Adults with untreated ADHD earn an estimated $77,000 less over their lifetime compared to adults without ADHD, reflecting the condition’s compounding effects on educational attainment and occupational performance. (American Journal of Psychiatry)
  The economic burden of ADHD in the United States is estimated at over $100 billion annually, including healthcare, education, and lost productivity costs.
• Stimulant medications for ADHD — methylphenidate and amphetamine salts — produce measurable improvements in working memory, attention, and executive function in approximately 70 to 80% of individuals who use them. (NEJM)
  These medications normalize dopamine and norepinephrine signaling in the prefrontal cortex, producing cognitive benefits that are real and clinically meaningful — distinct from the enhancement effects sought by non-ADHD users.
• Children with ADHD who receive consistent treatment show significantly better long-term academic and occupational outcomes than untreated peers, with reduced rates of substance use, depression, and anxiety in adulthood. (Journal of Child Psychology and Psychiatry)
  The case for early, consistent treatment is supported by both short-term and long-term outcome data.

For data on how ADHD and other cognitive challenges affect students specifically, see our article on Student Brain Health and Academic Performance Statistics.

Treatment Access and the Mental Health Care Gap

The gap between the prevalence of mental health conditions and access to care is one of the most significant public health failures of the modern era. Scale, stigma, cost, and workforce shortages all contribute to a treatment landscape that leaves the majority of affected individuals without adequate support.

• Only about 50% of people with a mental illness in high-income countries receive any treatment. (WHO)
  In low- and middle-income countries, the treatment gap exceeds 75% — meaning three out of four people with a mental health condition receive no care at all.
• The median delay between onset of mental illness symptoms and first treatment is 11 years. (World Psychiatry)
  This extraordinary delay — driven by stigma, lack of awareness, and access barriers — means that the structural brain changes associated with untreated mental illness accumulate for over a decade before intervention begins.
• There is a global shortage of approximately 1.18 million mental health workers, with the vast majority of the deficit in low- and middle-income countries. (WHO Mental Health Atlas)
  In some low-income countries, there is fewer than one psychiatrist per million people — a ratio that makes meaningful population-level mental health care structurally impossible.
• Psychotherapy — particularly cognitive behavioral therapy (CBT) — is effective for depression and anxiety in approximately 50 to 60% of treated individuals and produces lasting changes in brain function visible on neuroimaging. (JAMA Psychiatry)
  fMRI studies show that successful CBT normalizes prefrontal-amygdala connectivity in anxiety disorders and reduces hyperactivation of subcortical emotional circuits in depression.
• Digital mental health interventions — including app-based CBT and teletherapy — have expanded access significantly, with studies showing efficacy comparable to in-person care for mild to moderate depression and anxiety. (npj Digital Medicine)
  The COVID-19 pandemic accelerated the adoption of telehealth for mental health, with telemental health visits increasing by over 1,000% in the United States between 2019 and 2021. (JAMA Network Open)
• The United States spent approximately $280 billion on mental health services in 2023, yet an estimated 60% of adults with a mental illness still received no mental health services in that year. (SAMHSA)
  Spending is concentrated in inpatient and crisis care rather than in preventive and early intervention services — an allocation pattern that produces poor population health outcomes at high cost.

Mental Health, Cognitive Reserve, and Dementia Risk

The long-term relationship between mental health history and dementia risk is one of the most clinically important findings in brain health research. Several psychiatric conditions, when inadequately treated over years, meaningfully increase the probability of cognitive decline and dementia in later life.

• A history of depression is associated with a 65% higher lifetime risk of developing dementia, with the risk compounding with each additional depressive episode. (JAMA Psychiatry)
  This relationship persists after controlling for age, vascular risk factors, and other confounders — suggesting a direct neurobiological link rather than a shared risk factor explanation.
• Chronic anxiety in midlife is associated with a 48% higher risk of dementia in later life. (BMJ Open)
  The mechanism likely involves sustained cortisol elevation, neuroinflammation, and the compounding effects of associated sleep disruption and reduced social engagement.
• Effective treatment of depression in midlife appears to reduce the excess dementia risk associated with the condition, supporting the neurological argument for timely intervention. (The Lancet Psychiatry)
  This finding has significant implications for how depression treatment is prioritized — not only as a quality-of-life intervention but as a long-term neuroprotective one.
• Social connection is a powerful buffer against both mental illness and cognitive decline, with socially isolated individuals showing a 50% increased risk of dementia and significantly higher rates of depression and anxiety. (NASEM Report on Social Isolation)
  The mechanisms overlap: social engagement stimulates cognitive activity, reduces stress hormones, and maintains the motivation for other brain-healthy behaviors.

For detailed statistics on dementia risk factors and prevention, see our article on Dementia and Alzheimer’s Statistics. For data on how age-related changes affect both mental health and cognition across the lifespan, see Brain Health Statistics by Age.

Key Takeaways

• An estimated 970 million people worldwide live with a mental health or substance use disorder — roughly one in eight — yet mental health receives less than 2% of government health budgets on average globally, a structural mismatch with significant neurological consequences. (WHO)
• Depression is associated with up to 20% hippocampal volume reduction in recurrent episodes, and people with untreated depression are 2.5 times more likely to develop dementia — making timely treatment a neurological preservation strategy, not only a quality-of-life one. (British Journal of Psychiatry, JAMA Psychiatry)
• Anxiety disorders, affecting 284 million people globally, impair working memory through attentional competition with threat-monitoring processes and alter white matter connectivity in regions governing emotional regulation. (IHME, Psychological Science)
• The median delay between symptom onset and first treatment for mental illness is 11 years — meaning structural brain changes associated with untreated psychiatric conditions accumulate for over a decade before intervention begins for most people. (World Psychiatry)
• Psychotherapy, particularly CBT, produces measurable changes in brain function visible on neuroimaging — confirming that effective mental health treatment changes brain structure and function, not merely subjective symptom experience. (JAMA Psychiatry)

Explore the Full Brain Health Statistics Series

• Brain Health Statistics: 50+ Key Facts (2026)
• Dementia and Alzheimer’s Statistics
• Sleep and Brain Health Statistics
• Nootropics Industry Statistics and Market Data
• Mental Health and Cognitive Function Statistics
• Brain Health Statistics by Age
• Exercise and Brain Health Statistics
• Screen Time and Brain Health Statistics
• Nutrition and Brain Health Statistics
• Stress and the Brain: Key Statistics
• Student Brain Health and Academic Performance Statistics
• Creativity and the Brain: Key Statistics
• Biohacking Statistics and Trends
• AI and Cognitive Impact Statistics
• Brain Injury and Concussion Statistics